✦ LIBER ✦

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A

✍ Scribed by C. L. KEMPTON; T. C. ABSHIRE; R. A. DEVERAS; W. K. HOOTS; J. C. GILL; C. M. KESSLER; N. S. KEY; B. A. KONKLE; P. KURIAKOSE; D. E. MACFARLANE; G. BERGMAN

Book ID: 114728989
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 187 KB
Volume: 18
Category: Article
ISSN: 1351-8216
DOI: 10.1111/j.1365-2516.2012.02789.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The safety and efficacy of B-domain dele

The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update

✍ J. M. Lusher; D. A. Roth 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB

Efficacy and inhibitor development in pr

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII

✍ Alessandro Gringeri; Annarita Tagliaferri; Giuseppe Tagariello; Massimo Morfini; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Continuous infusion of B-domain deleted

Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience

✍ N. Stieltjes; C. Altisent; G. Auerswald; C. Négrier; P. Pouzol; J. Reynaud; V. R 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

Comparative immunogenicity of recombinan

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII

✍ E. T. Parker; H. N. Craddock; R. T. Barrow; P. Lollar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB

Clinical evaluation of moroctocog alfa (

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII

✍ M. RECHT; L. NEMES; M. MATYSIAK; M. MANCO-JOHNSON; J. LUSHER; M. SMITH; P. MANNU 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Efficacy and inhibitor development in pr

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII – clarification of Kogenate inhibitor data

✍ Peter Larson 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB